ARMSP-2 (Recombinant)

Recombinant Protein · expressed in HEK293
Citation tracking pending
Recombinant human Age-related maculopathy susceptibility protein 2 (ARMS2, UniProt P0C7Q2), expressed in HEK293 cells. Full 107 aa sequence. Suited for antibody validation, protein–protein interaction studies, and in vitro AMD research models.
Expression system
HEK293
Cat. #
REC-ARMSP2

In stock

SKU
REC-ARMSP2
$498.00

Target Overview

ARMSP-2 (REC-ARMSP2) is a recombinant form of human Age-related maculopathy susceptibility protein 2, encoded by the ARMS2 gene (UniProt P0C7Q2). The native protein is 107 amino acids in length and localises to the cytoplasm, though its precise molecular function remains under active investigation — a feature that makes well-characterised recombinant material particularly valuable for biochemical study. This recombinant is produced in HEK293 mammalian cells, an expression system that supports human-compatible post-translational processing, which is relevant when studying protein–protein interactions or generating antibody validation standards that faithfully represent the endogenous form. Researchers use this recombinant in several in vitro contexts. As a positive control antigen, it is directly compatible with the matched Triple Point Biologics antibody (RP-ARMSP2) for Western blot titration, dot-blot sensitivity checks, and immunohistochemistry optimisation. Because ARMS2 has no assigned enzymatic activity, the primary utility of the recombinant is as a binding partner or structural probe: it can serve as a capture ligand in pull-down or co-immunoprecipitation experiments designed to identify interacting partners, and as a calibration standard in quantitative immunoassays (ELISA, Luminex) targeting the endogenous protein in ocular or systemic samples. The ARMS2 locus has been extensively genotyped in age-related macular degeneration (AMD) cohorts, and the gene's promoter region has been characterised for transcription-factor binding activity (Zhang PW et al., 2025, bioRxiv). Recombinant ARMS2 protein supports functional follow-up of such genetic studies — for example, confirming that variant-associated changes in expression translate to detectable differences in protein level or binding behaviour. With a 107-residue sequence, the recombinant is also a tractable antigen for epitope-mapping experiments and for raising or validating monoclonal antibodies against defined regions of the protein.

Background

The ARMS2 gene, located at chromosomal locus 10q26.13, encodes a 107-amino-acid cytoplasmic protein whose biological function has not been fully resolved despite more than a decade of intensive genetic investigation. The locus sits in one of the strongest AMD-association regions in the human genome, identified through multiple large-scale genome-wide association studies, and variants at this locus — particularly the non-synonymous SNP rs10490924 (A69S) and a disease-associated indel in the 3′ UTR — rank among the highest-risk common genetic factors studied in AMD research to date. Precisely what ARMS2 protein does at the molecular level remains a subject of published debate. Proposed roles have included mitochondrial localisation, complement-pathway modulation, and interaction with extracellular matrix components, though none has been established as canonical. The lack of an assigned enzymatic activity or well-defined binding domain makes recombinant protein tools especially important: researchers rely on pure, full-length recombinant ARMS2 to interrogate these hypotheses directly in pull-down assays, surface plasmon resonance, and co-immunoprecipitation experiments. In AMD genetic-architecture research, ARMS2 variants are routinely analysed alongside complement factor H (CFH) and HTRA1 variants. Ranga D et al. (2026, Indian J Ophthalmol) examined how ARMS2, HTRA1, and CFH variants collectively influence the clinical phenotypes of AMD patients, illustrating how protein-level studies of ARMS2 fit within a broader complement- and protease-biology framework. Separately, Villarruel Hinnerskov JM et al. (2026, Immun Ageing) investigated associations between complement regulatory proteins and geographic atrophy progression rate, a context in which ARMS2 genotype is a standard covariate. At the transcriptional level, Zhang PW et al. (2025, bioRxiv) characterised an AMD-associated SNP in the ARMS2 promoter that affects c-ABL kinase binding, providing a functional handle on how genetic risk at this locus may operate through altered transcription-factor recruitment. Recombinant ARMS2 protein supports the protein-level arm of such studies — for instance, confirming translation of identified transcripts or quantifying protein output from variant versus reference allele constructs. Researchers working on ARMS2 biology can pair this recombinant with the Triple Point Biologics matched antibody (RP-ARMSP2), validated for Western blot against human targets, to build internally consistent reagent sets for detection and functional experiments. Triple Point Biologics has supplied antibodies against proteinases and their inhibitors since 1994, and this recombinant is produced to the same lot-consistency standards applied across the REC- series.

Applications

  • Antibody validation positive control: Western blot titre optimisation paired with matched antibody RP-ARMSP2
  • Dot-blot and ELISA calibration standard for quantifying ARMS2 protein in human ocular or plasma samples
  • Pull-down / co-immunoprecipitation bait protein for identifying ARMS2 cytoplasmic binding partners
  • Surface plasmon resonance (SPR) or bio-layer interferometry (BLI) binding-affinity measurements with candidate interactors
  • Immunohistochemistry (IHC) antigen control for titrating RP-ARMSP2 on retinal tissue sections
  • Epitope-mapping antigen for monoclonal antibody development or competitive ELISA design
  • In vitro protein-expression reference standard for allele-specific expression studies comparing ARMS2 variant constructs

References

  1. Villarruel Hinnerskov JM et al. Complement regulatory proteins are associated with progression rate of geographic atrophy secondary to age-related macular degeneration. Immun Ageing. 2026. doi:10.1186/s12979-026-00562-y PMID: 41709226
  2. Han YK et al. Brain imaging data and summary data-based Mendelian randomization analysis reveal the impact of multiorgan aging on schizophrenia. Front Psychiatry. 2025. doi:10.3389/fpsyt.2025.1730143 PMID: 41704524
  3. Ranga D et al. Impact of age-related maculopathy susceptibility 2, high-temperature requirement A serine peptidase 1, and complement factor H genetic variants on clinical phenotypes of age-related macular degeneration. Indian J Ophthalmol. 2026. doi:10.4103/IJO.IJO_1395_25 PMID: 41581044
  4. Farashi S et al. HTRA1/lncRNA HTRA1-AS1 dominates in age-related macular degeneration reticular pseudodrusen genetic risk with no complement involvement. Nat Commun. 2025. doi:10.1038/s41467-025-65903-9 PMID: 41361163
  5. Zhang PW et al. Identification and functional characterization of an AMD associated c-ABL binding SNP streak within the ARMS2 gene promoter region. bioRxiv. 2025. doi:10.1101/2025.10.27.684937 PMID: 41279129

Additional Specifications

Storage Buffer 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol
Endotoxin Level <0.1 EU/µg by LAL
Purity (%) >90% by SDS-PAGE
Expression System HEK293
Subcellular Localization Subcellular localization not yet annotated

Frequently Asked Questions

What molecular weight band should I expect for ARMSP-2 recombinant protein on SDS-PAGE or Western blot?

The native ARMS2 protein is 107 amino acids, giving a predicted molecular weight of approximately 12 kDa. On SDS-PAGE under reducing conditions, the recombinant (REC-ARMSP2) produced in HEK293 cells typically migrates at 12–14 kDa. Minor upward shifts from any affinity tag or post-translational modifications introduced during mammalian expression are possible. Confirm purity visually — >90% by Coomassie staining is expected. When using RP-ARMSP2 for Western blot detection of this band, expect a clean signal in this low-MW range with minimal background at recommended antibody dilutions.

Does recombinant ARMSP-2 represent the full-length protein or a processed isoform?

REC-ARMSP2 covers the full 107-amino-acid sequence of human ARMS2 (UniProt P0C7Q2). No truncations or isoform-specific splicing have been introduced. Because this recombinant is expressed in HEK293 mammalian cells, it undergoes human-compatible post-translational processing, making it a closer structural proxy to the endogenous retinal protein than bacterially expressed material would be. This is particularly relevant for researchers studying protein–protein interactions or using the recombinant as an antibody validation standard, where conformational fidelity to the native form matters.

Does ARMSP-2 have known enzymatic activity or a defined substrate for activity assays?

ARMS2 has no assigned enzymatic activity in current literature — its molecular function remains under active investigation, and no consensus substrate has been established. REC-ARMSP2 is therefore not intended for classical enzyme activity assays. Its primary in vitro utility is as a well-characterised recombinant antigen: positive control for Western blot, dot-blot sensitivity calibration, IHC optimisation, and as a binding partner in pull-down or co-immunoprecipitation experiments designed to probe ARMS2 protein–protein interactions. Researchers designing functional assays should treat any observed activity as exploratory.

What buffer conditions are recommended for ARMSP-2 recombinant protein in pull-down or binding assays?

REC-ARMSP2 is supplied in 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — a physiologically compatible formulation suitable for most binding and pull-down experiments without buffer exchange. If your assay requires lower glycerol (e.g., for SPR or BLI), dialysis or dilution into a matched Tris-NaCl buffer at pH 7.4–7.5 is appropriate; keep glycerol above 5% if the diluted protein will be stored before use. Avoid repeated freeze-thaw cycles — single-use aliquots are strongly recommended to preserve protein integrity across experiments.

What starting concentration of ARMSP-2 recombinant should I use for a dot-blot sensitivity check?

For an initial dot-blot sensitivity titration with the matched antibody RP-ARMSP2, a useful starting range is 50–500 ng of REC-ARMSP2 per spot. Begin at 250 ng and titrate down in threefold steps to identify your antibody's detection limit. Because the ARMS2 protein is small (~12 kDa), signal intensity can drop quickly at low loads — establishing this sensitivity threshold before moving to cell lysate experiments saves significant optimisation time. Endotoxin levels are <0.1 EU/µg by LAL, so background signal in functional binding assays should remain low.

Can I use REC-ARMSP2 as a positive control antigen for Western blot with the matched RP-ARMSP2 antibody?

Yes — this is a primary validated use case. Load 50–200 ng of REC-ARMSP2 per lane alongside your cell or tissue lysates. Run on a 12–15% polyacrylamide gel to resolve the ~12–14 kDa band cleanly, then blot and probe with RP-ARMSP2 (see /anti-armsp-2-rabbit-polyclonal-antibody for recommended dilutions). The recombinant and antibody are produced from the same target sequence in the same lab, so antigen–antibody compatibility is guaranteed — no cross-reactivity ambiguity. This pairing is directly useful for titrating primary antibody concentration and confirming specificity before committing to experimental samples.

How much ARMSP-2 recombinant protein should I load for Western blot positive control with RP-ARMSP2?

A load of 100 ng per lane is a reliable starting point for Western blot positive control when detecting with RP-ARMSP2. If your gel system resolves small proteins efficiently (12–15% acrylamide, Tris-tricine format recommended for sub-15 kDa targets), you can reduce this to 50 ng once the antibody dilution is optimised. Loading too little of a small protein like ARMSP-2 risks a faint or absent band, particularly if transfer efficiency for low-MW proteins has not been separately validated. Run the recombinant lane adjacent to a molecular weight ladder with clear 10–15 kDa markers.

How should I store and handle ARMSP-2 recombinant protein to maintain stability long-term?

Store REC-ARMSP2 at -20°C in single-use aliquots immediately upon receipt. The supplied buffer — 50 mM Tris-HCl pH 7.5, 150 mM NaCl, 10% glycerol — provides cryoprotection, but repeated freeze-thaw cycles will progressively degrade a small protein like ARMSP-2. Aliquot to your typical working volume (e.g., 5–10 µg per tube) before first use. Once thawed, keep on ice and use within the same working session. Avoid storage in standard -20°C frost-free freezers that cycle temperature. Under correct conditions, stability is expected for 12 months from date of receipt.

Validation imagery coming soon

Western blot validation figures for REC-ARMSP2 will be published here as they are produced in-house.

If you would like to see existing validation data for this antibody before publication, request a sample copy.

  • Product Datasheet

    Full specifications, immunogen, validation, and recommended protocols.

    Request PDF →
  • Certificate of Analysis (COA)

    Lot-specific QC report. Available on request for any catalog lot.

    Request COA →
  • Safety Data Sheet (SDS)

    Handling, storage, and disposal guidance per regulatory standards.

    Request SDS →